Undifferentiated pleomorphic sarcoma (UPS)
Clinical trials for Undifferentiated pleomorphic sarcoma (UPS) explained in plain language.
Never miss a new study
Get alerted when new Undifferentiated pleomorphic sarcoma (UPS) trials appear
Sign up with your email to follow new studies for Undifferentiated pleomorphic sarcoma (UPS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new drug boost chemotherapy against rare sarcomas?
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called DT-7012 to standard chemotherapy (doxorubicin) helps people with advanced soft tissue sarcoma, specifically two subtypes: undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Participants receive either…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Triple attack on aggressive sarcoma: can radiation, immunotherapy, and chemo shrink tumors before surgery?
Disease control Not yet recruitingThis phase 2 trial tests a three-part treatment for people with high-risk undifferentiated pleomorphic sarcoma (UPS), a rare cancer of soft tissue. Participants receive focused radiation (SBRT), the immunotherapy drug toripalimab, and a lower dose of the chemotherapy drug liposom…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a Patient's own immune cells fight advanced sarcoma?
Disease control Not yet recruitingThis phase 2 trial is testing whether lifileucel, a therapy made from a patient's own tumor-infiltrating lymphocytes (immune cells), can shrink tumors in adults with advanced soft tissue sarcoma. Participants will have their tumor removed to create the personalized therapy, then …
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)
Phase 2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC